Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Dave Adair
AddedMar 31, 2024
UpdatedMay 31, 2026
Dave Adair

Dave Adair

Co-Founder, Solas BioVentures

CrunchbaseLinkedIn

Dave Adair's Career

Solas BioVentures
Solas BioVentures

Chattanooga, TN, US

Co-Founder
Glenveigh Medical
Glenveigh Medical

Chattanooga, TN, US

Board Member· Board
InterShunt
InterShunt

Plymouth, MN, US

Board Member· Board
NX Prenatal
NX Prenatal

Louisville, KY, US

Board Member· Board
Advanced Catheter Therapies
Advanced Catheter Therapies

Chattanooga, TN, US

Board Member· Board
BioStable Science & Engineering
BioStable Science & Engineering

Austin, TX, US

Board Member· Board
Arrivo BioVentures
Arrivo BioVentures

Morrisville, NC, US

Board Member· Board
Francis Medical
Francis Medical

Maple Grove, MN, US

Board Member· Board
Knopp Biosciences
Knopp Biosciences

Pittsburgh, PA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Dave Adair's Career

Solas BioVentures
Solas BioVentures
Investment FirmInvestment Firm192015Chattanooga, TN, US
Co-Founder

Leadership at Solas BioVentures

Mark HackettMark HackettCo-Founder
Glenveigh Medical
Glenveigh Medical
Pre-Seed$3.4M52007Chattanooga, TN, US
Board Member· Board
InterShunt
InterShunt

Plymouth, MN, US

Board Member· Board
NX Prenatal
NX Prenatal
Seed$8.1M52013Louisville, KY, US
Board Member· Board

Leadership at NX Prenatal

Brian BrohmanBrian BrohmanFounder

Similar to NX Prenatal

NX PharmagenNX PharmagenLouisville, KY, USDiagnostics, Imagingest. 2010NX PharmagenLouisville, KY, US · est. 2010

NX PharmaGen develops and monetizes mature clinical-stage technologies, focusing on disruptive diagnostic solutions.

Pre-Seed · $7.2M6
KellBenxKellBenxMassapequa, NY, USPrenatal Testingest. 2010KellBenxMassapequa, NY, US · est. 2010

KellBenx Inc: Biotech service provider specializing in non-invasive prenatal diagnosis.

Seed · $16.7M7
ProteogenixProteogenixCosta Mesa, CA, USDiagnostic Testsest. 2002ProteogenixCosta Mesa, CA, US · est. 2002

ProteoGenix Inc. develops and commercializes diagnostic tests for pregnancy-related complications.

Series A · $39.2M30
Cradle GenomicsCradle GenomicsSan Diego, CA, USGenetic Testing, Prenatal Testingest. 2018Cradle GenomicsSan Diego, CA, US · est. 2018

Cradle Genomics: Transforming prenatal care with comprehensive early-stage NIPT solutions.

Series A · $23.1M34
Advanced Catheter Therapies
Advanced Catheter Therapies
Series A$14.2M52008Chattanooga, TN, US
Board Member· Board

Similar to Advanced Catheter Therapies

Cagent VascularCagent VascularWayne, PA, USMedical Devicesest. 2014Cagent VascularWayne, PA, US · est. 2014

Cagent Vascular: US-based medical device manufacturer specializing in cardiovascular disease treatment.

Series A · $21.9M41
ThrombolexThrombolexDoylestown, PA, USMedical Devicesest. 2016ThrombolexDoylestown, PA, US · est. 2016

Thrombolex innovates efficient endovascular catheters for precise, cost-effective treatment of A+VTE conditions since 2016.

Seed · $16.8M11
Bluegrass Vascular TechnologiesBluegrass Vascular TechnologiesSan Antonio, TX, USMedical Devicesest. 2011Bluegrass Vascular TechnologiesSan Antonio, TX, US · est. 2011

Bluegrass Vascular Technologies: Innovating lifesaving vascular access devices and methods.

Series A · $4.5M6
BioStable Science & Engineering
BioStable Science & Engineering
Series C$10.8M62008Austin, TX, US
Board Member· Board

Leadership at BioStable Science & Engineering

John WheelerJohn WheelerBoard Member
David StrongDavid StrongBoard Member
Brian LadenBrian LadenBoard Member
Arrivo BioVentures
Arrivo BioVentures
Series B$94.3M122015Morrisville, NC, US
Board Member· Board

Leadership at Arrivo BioVentures

Michael F. AckermannMichael F. AckermannBoard Member
Stephen ButtsStephen ButtsCEO
Francis Medical
Francis Medical

Maple Grove, MN, US

Board Member· Board
Knopp Biosciences
Knopp Biosciences
Series C$164M102004Pittsburgh, PA, US
Board Member· Board

Leadership at Knopp Biosciences

Shane KovacsShane KovacsBoard Member
Gregory HebrankGregory HebrankCo-Founder
Robert BowserRobert BowserCo-Founder
Dr. Michael E. BozikDr. Michael E. BozikCEO

Similar to Knopp Biosciences

KBP BiosciencesKBP BiosciencesPrinceton, NJ, USDrug Developmentest. 2007KBP BiosciencesPrinceton, NJ, US · est. 2007

KBP pioneers in drug development, focusing on lung, heart, kidney diseases, and immunology, leveraging unique insights for innovative therapies.

Series A · $76M51
Caden BiosciencesCaden BiosciencesMadison, WI, USPharmaceuticalsest. 2000Caden BiosciencesMadison, WI, US · est. 2000

Discovering & developing pharmaceuticals for nervous system disorders.

Series A · $5.8M5

Dave Adair's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakChi-hyung SongChi-hyung SongBoard Member · DunamuHaeil YiHaeil YiCo-Founder · DunamuHyoung-nyon KimHyoung-nyon KimCo-Founder · Dunamu

People Similar to Dave Adair

Greg MaddenGreg MaddenBoard Member · AlloCureDoug GivenDoug GivenBoard Member · Arrowhead PharmaceuticalsKONSTANTINOS ALATARIS, PhDKONSTANTINOS ALATARIS, PhDFounder · NevroMichael PelliniMichael PelliniBoard Member · Foundation MedicineNorman WeldonNorman WeldonCo-Founder · AtriCureAlan KaganovAlan KaganovBoard Member · AtriCure